结核分枝杆菌联合药敏试验的研究进展

doi:10.3969/j.issn.1000-6621.2015.01.016

摘要/Abstract

摘要： 结核病仍然是威胁全球性的传染病，随着耐多药和广泛耐药结核分枝杆菌的出现，结核病的控制变得更加困难。为了防止结核分枝杆菌对某种药物耐药，WHO推荐结核病的治疗以几种不同的药物联合治疗为主。对于耐药结核病的治疗应根据药敏结果采取个体化治疗方案。目前的药敏试验大都是针对单药进行的，但是有时即使单药药敏试验结果是耐药，临床中与其他药物联合使用仍有较好的治疗效果，这提醒我们几种药物联合使用可能会增强其抗菌活性。当前存在一线药物耐药问题严重以及二线药物价格昂贵、毒性大等问题，因此迫切需要我们寻找新的抗结核化疗方案来控制耐药结核病的流行。在建立新的化学方案前，进行可量化的重复实验来评估方案中几种药物的联合抗菌活性是十分重要的。

关键词: 结核分枝杆菌, 微生物敏感性试验

Abstract: Tuberculosis remains a threat to global pandemic, it becomes more difficult to control TB due to the emergence of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. Preventing the resistance to a paticular drug, WHO has recommended the combined modality therapy with several drugs as the main method in the treatment of TB. Individualized treatment plan, based on the drug susceptibility results, should be taken in the treatment of drug-resistant TB. So far, the drug susceptibility test is mostly carried out for monotherapy. However, in some cases, even the single drug susceptibility results are resistant, the combined modality therapy still performances better therapeutic effect, which reminds us that the combination of several drugs used in treatment may enhance its antibacterial activity. At present, because of the severe drug resistance of first-line drugs and the shortcoming of second-line drugs (such as price，toxicity and so on), we urgently need to find a new anti-TB chemotherapy to control the prevalence of drug-resistant. Before creating a new chemistry program, it is important to conduct quantified experiments repeatedly to evaluate the antimicrobial activity of the combined modality therapy.

Key words: Mycobacterium tuberculosis, Microbial sensitivity tests

张琳琳，杨华，肖和平. 结核分枝杆菌联合药敏试验的研究进展[J]. 中国防痨杂志, 2015, 37(1): 86-89. doi: 10.3969/j.issn.1000-6621.2015.01.016

ZHANG Lin-lin, YANG Hua, XIAO He-ping. The progress of combined drug susceptibility test with Mycobacterium tuberculosis[J]. Chinese Journal of Antituberculosis, 2015, 37(1): 86-89. doi: 10.3969/j.issn.1000-6621.2015.01.016

参考文献

［1］Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297.
［2］Moody JA. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. Washington DC: American Society for Microbiology, 1992：22.
［3］文亚坤, 曹萌, 邹琳, 等. 碳青霉烯类抗生素耐药铜绿假单胞菌的体外联合药敏研究. 中国抗生素杂志, 2012, 37(7): 536-538.
［4］Rey-Jurado E, TudóG, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents, 2013, 41(3): 278-280.
［5］Rosenblatt JE, Stewart PR. Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli. Antimicrob Agents Chemother, 1974, 6(1): 84-92.
［6］Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis, 1978, 137(2): 122-130.
［7］Yu VL, Felegie TP, Yee RB, et al. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J Infect Dis, 1980, 142(4): 602-607.
［8］Yoon J, Urban C, Terzian C, et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2004, 48(3): 753-757.
［9］Cetin ES, Tekeli A, Ozseven AG, et al. Determination of In Vitro Activities of Polymyxin B and Rifampin in Combination with Ampicillin/Sulbactam or Cefoperazone/Sulbactam against Multidrug-Resistant Acinetobacter baumannii by the E-test and Checkerboard Methods. Jpn J Infect Dis, 2013, 66(6): 463-468.
［10］Cavalieri SJ, Biehle JR, Sanders WE Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1995, 39(7): 1542-1545.
［11］Bergmann JS, Woods GL. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis, 1998, 2(8): 621-626.
［12］Bhusal Y,Shioshira CM,Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.Int J Antimicrob Agents，2005，26(4):292-297.
［13］Rey-Jurado E, Tudó G, Martínez JA, et al. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis. Tuberculosis (Edinb)，2012, 92(3): 260-263.
［14］Caleffi-Ferracioli KR, Maltempe FG, Siqueira VL, et al. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method. Tuberculosis (Edinb), 2013, 93(6): 660-663.
［15］Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise,and prospects for the future. J Infect Dis, 2012,205(Suppl 2):S 241-249.
［16］Kaur D, Khuller GK. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria. Int J Antimicrob Agents, 2001, 17(1): 51-55.
［17］De Logu A, Onnis V, Saddi B, et al. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother, 2002, 49(2): 275-282.
［18］Rodriguez Díaz JC, Ruiz M, Lopez M, et al. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2003, 21(4): 354-356.
［19］Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297.
［20］de Steenwinkel JE, de Knegt GJ, ten Kate MT, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother, 2010, 65(12): 2582-2589.
［21］Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Future Microbiol, 2011, 6(6): 617-633.
［22］Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis, 2003,7（1）:6-21.

[1]	李爱芳, 崔晓利, 康磊, 雷静, 党丽云, 杨翰. 荧光PCR探针熔解曲线法检测结核分枝杆菌耐药性的价值[J]. 中国防痨杂志, 2020, 42(9): 998-1001.
[2]	盛杰, 朱洋, 地里下提·阿不力孜, 唐伟, 古甫丁, 宋兴华. 表型与分子药物敏感性试验对术后耐药骨关节结核患者化疗的指导与效果分析[J]. 中国防痨杂志, 2020, 42(8): 838-844.
[3]	孙晴, 黄海荣, 王桂荣. 贝达喹啉、氯法齐明和德拉马尼对常见致病性非结核分枝杆菌体外抑菌活性及耐药机制的研究进展[J]. 中国防痨杂志, 2020, 42(8): 880-884.
[4]	宋怡蒙, 李远春, 贺文从, 何萍, 包晶晶, 刘春法, 刘东鑫, 王鑫洋, 赵雁林, 李燕明. 荧光PCR探针熔解曲线技术检测MTB耐药性的成本分析[J]. 中国防痨杂志, 2020, 42(7): 712-717.
[5]	包训迪, 江跃, 梁锁, 程红燕, 夏广秀, 王超, 叶倩, 王舒, 王庆. 安徽省非结核分枝杆菌临床分离率及人群分布和耐药性分析[J]. 中国防痨杂志, 2020, 42(7): 718-724.
[6]	马进宝, 任斐, 曾令城, 陈明伟. 2015—2019年西安市680例耐多药结核病患者耐药情况分析[J]. 中国防痨杂志, 2020, 42(6): 609-613.
[7]	张静, 陈曦, 王彬, 付雷, 陆宇, 陈效友. 改良单叠氮丙啶-荧光定量PCR法的建立及其检测抗结核药物活性的价值[J]. 中国防痨杂志, 2020, 42(5): 472-480.
[8]	李鑫娜, 申辛欣, 王瑞白, 段素霞, 张瑞卿, 王瑞欢, 白雪丁, 凡国豪, 王金荣, 高源, 陈子巍, 马学军. 探针导向重组酶介导等温扩增法检测MTB rpoB基因突变的应用价值[J]. 中国防痨杂志, 2020, 42(5): 481-488.
[9]	杨翰,杨静芬,伍浩,崔晓利,党丽云. 微孔板法在一线抗结核药物敏感性试验中的应用价值[J]. 中国防痨杂志, 2020, 42(4): 380-384.
[10]	简奕娈,吴龙章,古卓云. 18例五官非结核分枝杆菌病患者的临床特征及疗效分析[J]. 中国防痨杂志, 2020, 42(3): 255-258.
[11]	陈燕梅,黄新春,孙琦,张晨晨,温文沛,陈亮. 2016年广东省涂阴培阳肺结核患者耐药情况分析[J]. 中国防痨杂志, 2020, 42(3): 272-275.
[12]	蒋明霞, 晁秀珍, 王兆芬, 马斌忠, 马永成, 王蓉, 王朝才, 李尔琛, 魏於家, 李咏雪, 张琪. 青海省南部地区154株结核分枝杆菌临床分离株耐药性检测结果分析[J]. 中国防痨杂志, 2020, 42(12): 1289-1293.
[13]	冯莹, 马进宝, 杨翰, 杨元利, 任斐. 93例结核性脑膜炎患者脑脊液分离株耐药性检测结果分析[J]. 中国防痨杂志, 2020, 42(11): 1177-1182.
[14]	应若嫣, 黄晓辰, 王洁, 刘一典, 沙巍, 杨华. 耐药MTB分离株对不同组合抗结核药品体外药物敏感性试验的结果分析[J]. 中国防痨杂志, 2020, 42(11): 1183-1182.
[15]	杨映晖, 伍定辉, 苏伟明, 董春萍, 姚向阳. 基因芯片法在结核分枝杆菌耐药基因快速诊断中的应用价值[J]. 中国防痨杂志, 2020, 42(11): 1191-1195.